• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Chester C. Iii Buckenmaier, John F. Capacchione, +6 authors Péter Bedőcs
  • Medicine
  • Anesthesia and analgesia
  • 2012 (First Publication: 1 April 2012)
  • BACKGROUND: Lipid emulsion (20%) is advocated as a rescue drug for local anesthetic toxicity. No study has measured the impact of lipid emulsion therapy on postmortem local anesthetic serum levels.Expand
  • Olivia M. Merkel, Rudolf Urbanics, +5 authors János Szebeni
  • Materials Science, Medicine
  • Biomaterials
  • 2011 (First Publication: 1 July 2011)
  • Complement activation by polymeric gene and drug delivery systems has been overlooked in the past. As more reports appear in the literature concerning immunogenicity of polymers and their impact onExpand
  • János Szebeni, Péter Bedőcs, Domokos Csukás, László Rosivall, Rolf Bünger, Rudolf Urbanics
  • Medicine
  • Advanced drug delivery reviews
  • 2012 (First Publication: 1 December 2012)
  • Intravenous administration of low (milligram) doses of nanoparticulate materials in pigs can lead to acute cardiopulmonary, hemodynamic, hematological, biochemical and dermatological changes withinExpand
  • János Szebeni, Péter Bedőcs, +9 authors Yechezkel Chezy Barenholz
  • Medicine
  • Nanomedicine : nanotechnology, biology, and…
  • 2012 (First Publication: 1 February 2012)
  • UNLABELLED Hypersensitivity reactions to liposomal drugs, often observed with Doxil and AmBisome, can arise from activation of the complement (C) system by phospholipid bilayers. To understand theExpand
  • János Szebeni, Péter Bedőcs, +4 authors Yechezkel Chezy Barenholz
  • Medicine
  • Journal of controlled release : official journal…
  • 2012 (First Publication: 10 June 2012)
  • PEGylated liposomal doxorubicin (Doxil) has been used in cancer chemotherapy for 16 years. Clinical experience shows that it can cause mild-to-severe hypersensitivity (infusion) reactions, which areExpand